[1]钱习军.99Tcm-MIBI显像对肿瘤多药耐药检测的应用[J].国际放射医学核医学杂志,2002,26(4):173-176.
　QIAN Xi-jun.The application of 99Tcm-MIBI imaging to detect multidrug resistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):173-176.
点击复制

99Tcm-MIBI显像对肿瘤多药耐药检测的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第4期
页码:
173-176
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The application of 99Tcm-MIBI imaging to detect multidrug resistance
作者:
钱习军
210009 南京, 东南大学医学院血液肿瘤科
Author(s):
QIAN Xi-jun
Medical College of Southeast University, Jiangsu Nanjing 210009, China
关键词:
多药耐药; 99Tcm-甲氧基异丁基异腈; P-糖蛋白; 多药耐药相关蛋白; 肿瘤
Keywords:
multidrug resistance; 99Tcm-sestamibi; P-glycoprotein; multidrug resistance related protein; tumor
分类号:
R817.4
摘要:
MDR(多药耐药)是目前肿瘤化疗失败的主要原因,对MDR的检测可以帮助化疗决策的制定,从而使肿瘤患者得到更有效的治疗。99Tcm-MIBI(99Tcm-甲氧基异丁基异腈)是mdr1基因编码的P-gp(P-糖蛋白)和MRP(多药耐药相关蛋白)的转运底物,肿瘤细胞内99Tcm-MIBI摄取减低表明其P-gp的高表达,并与MRP的表达相关。因此,99Tc
Abstract:
Multidrug resistance is the main cause of chemotherapy failure,To detect multidrug resistance is helpful to develop chemotherapy regimens and more effective treatment of patients with tumors. 99Tcm-sestamibi is a transport sub-strate of mdr1-encoded P-glycoprotein and MRP.The lower 99Tcm-sestamibi accumulation indicates the higher expression of P-glycoprotein in tumor cells.It is also related to the expression of MRP.As a result,response to chemotherapy can be estimated before starting treatment by means of 99Tcm-sestamibi imaging and more effective protocol can be chosen.

参考文献/References:

[1] Shung-Shung S, Tih-Fang H, Shih-chuan T, et al. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results[J]. Cancer Lett, 2000, 153(1-2):95-100.
[2] Del-Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J]. J Nucl Med, 1997, 38(9):1348-1351.
[3] Del-Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistance (MDB1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients[J]. Eur J Nucl Med, 1997, 24(2):150-159.
[4] Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer[J]. J Nucl Med, 1998, 39(2):228-234.
[5] Andrews DW, Dss R, Kim S, et al. Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance[J]. Neurosurgery, 1997, 40(6):1323-1332.
[6] Kapucu LÖ, Akyüz C, Varal G, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi[J]. J Nucl Med, 1997, 38(2):243-247.
[7] Gruber A, Areström I, Xu D, et al. Multidrug resistance phenotype in leukaemia cells from patients with acute myelocytie leukaemia can be detected with 99Tcm-MIBI[J]. Br J Cancer, 1998, 77(11):1732-1736.
[8] Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy[J]. J Nucl Med, 1998, 39(7):1191-1197.
[9] Leitha T, Glaser C, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, P53 expression, or cell proliferation?[J]. Nucl Med Biol, 1998, 25(6):539-541.
[10] Fujii H, Nakamura K, Kubo A, et al. Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase 99Tcm-MIBI scintimammography[J]. Ann Nacl Med, 1998, 12(6):307-312.
[11] Kostakoglu L, Ruacan S, Ergün EL, et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer[J]. J Nucl Med, 1998, 39(6):1021-1026.
[12] Duran-Cordobes M, Moretti JL, De-Beco V, et al. Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines[J]. Nucl Med Commun, 1999, 20(5):433-437.
[13] Hendrikse NH, Franssen EJF, Van-der-Graaf WTA, et al.99Tcm-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein[J]. Br J Cancer, 1998, 77(3):353-358.
[14] Moretti JL, Duran-Cordobes M, Starzec A, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells[J]. J Nucl Med, 1998, 39(7):1214-1218.
[15] Chia-Hung K, Shih-Chuan T, Tse-Jia L, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings[J]. Cancer Res, 2001, 61(4):1412-1414.
[16] Chia-Hung K, Shih-Chuan T, Thi-Joung W, et al. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression multidrug resistance-related protein expression and other prognosis factors[J]. Br J Haematol, 2001, 113(2):369-374.
[17] Zhou J, Higashi K, Ueda Y, et al. Expression of multidrug resistance protein and messenger RNA correlate with 99Tcm-MIBI imaging in patients with lung cancer[J]. J Nucl Med, 2001, 42(10):1476-1483.
[18] Kabasakal L, Özker K, Hayward M, et al. Technetium-99m sestamibi uptake in human breast carinoma cell lines displaying glutathione-associated drug-resis tance[J]. Eur J Nucl Med, 1996, 23(5):568-570.

相似文献/References:

[1]杨波,刘长春,张勇,等.99Tcm-MIBI运动负荷-静息心肌灌注显像对冠心病患者经皮腔内冠状动脉血管成形术的疗效评价[J].国际放射医学核医学杂志,2009,33(1):37.[doi:10.3760/cma.j.issn.1673-4114.2009.01.037]
　YANG Bo,LIU Chang-chun,ZHANG Yong,et al.Evaluation of the outcomes of 99Tcm-MIBI stress-rest perfusion imaging in coronary heart disease with percutaneous transluminal coronary angioplasty[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):37.[doi:10.3760/cma.j.issn.1673-4114.2009.01.037]
[2]张一秋,石洪成.99Tcm-甲氧基异丁基异腈SPECT预测肺癌多药耐药及化疗疗效[J].国际放射医学核医学杂志,2008,32(6):329.
　ZHANG Yi-qiu,SHI Hong-cheng.Single photon emission computed tomography imaging using 99Tcm-methoxyisobuty-lisonitrile predict the multi-drug resistance and chemotherapy efficacy of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):329.
[3]白旭东,唐志刚,王学斌.99Tcm标记异腈类配合物的研究进展[J].国际放射医学核医学杂志,2005,29(1):19.
　BAI Xu-dong,TANG Zhi-gang,WANG Xue-bin.The development of 99Tcm labeled isonitrile complexes[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):19.
[4]贾志云,邓候富.99Tcm-甲氧基异丁基异腈显像在白血病中的应用价值[J].国际放射医学核医学杂志,2005,29(6):252.
　JIA Zhi-yun,DENG Hou-fu.The value of 99Tcm-sestamibi scintigraphy in leukemia[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):252.
[5]刘志军.99Tcm-MIBI显像在头颈部恶性肿瘤中的应用[J].国际放射医学核医学杂志,2004,28(5):203.
　LIU Zhi-jun.The application of 99Tcm-MIBI imaging in head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):203.
[6]赵韬.99Tcm-MIBI显像检测乳腺癌P-糖蛋白[J].国际放射医学核医学杂志,2004,28(6):262.
　ZHAO Tao.Application of 99Tcm-MIBI scintimammography to diagnose P-gP of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):262.
[7]袁志斌.核医学影像诊断多发性骨髓瘤的临床价值[J].国际放射医学核医学杂志,2003,27(4):162.
　YUAN Zhi-bin.The clinical value of radionulide scintigraphy in the assessing of multiple myeloma[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):162.
[8]金玉新.双核素心肌SPECT的研究进展[J].国际放射医学核医学杂志,2003,27(4):171.
　JIN Yu-xin.The progress of dual-isotope myocardial perfusion SPECT[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):171.
[9]何建华.99Tcm-MIBI用于乳腺癌诊断的评价[J].国际放射医学核医学杂志,2002,26(2):64.
　HE Jian-hua.Evaluation of 99Tcm-MIBI scintigraphy in the diagnosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):64.
[10]程兵.99Tcm-MIBI显像检测乳腺癌多药耐药[J].国际放射医学核医学杂志,2002,26(2):67.
　CHENG Bing.The appliciation of 99Tcm-MIBI scintimammography to diagnose multidrug resistance of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):67.
[11]黄建敏,曲雁,潘莉萍.恶性骨肿瘤多药耐药的99Tcm-MIBI体层显像研究[J].国际放射医学核医学杂志,2005,29(4):169.
　HUANG Jian-min,QU Yan,PAN Li-ping.Research of 99Tcm-MIBI SPECT imaging for assessment of multidrug resistance in Bone tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):169.

备注/Memo

备注/Memo:
收稿日期:2002-04-24。
作者简介:钱习军(1972-),女,安徽无为人,硕士研究生,主要从事肿瘤多药耐药机制及逆转的研究。
更新日期/Last Update: 1900-01-01